Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) dated March 4, 2020, announces the publication of the Annual Report for the year ended December 31, 2019. The filing serves as a notification to the US Securities and Exchange Commission regarding the availability of the full Annual Report and the Notice of the Annual General Meeting 2020. The document references unaudited preliminary results released on February 5, 2020, and includes a significant accounting adjustment regarding prior year equity balances.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for the 2019 period. These figures are contained within the referenced Annual Report 2019 and the preliminary results announcement. However, the filing details specific financial adjustments and related party transactions:
- Accounting Adjustment: A revision of £579 million was made to reallocate cumulative translation exchange and eliminate remaining non-controlling interest balances related to the 2018 acquisition of Novartis' interest in the Consumer Healthcare Joint Venture. This adjustment reduced 2019 reported retained earnings from £5,109 million to £4,530 million and shareholders' equity from £11,984 million to £11,405 million.
- Related Party Transactions:
- Royalties due to Innoviva Inc.: £215 million (2018: £209 million).
- Balance payable to Innoviva Inc.: £63 million.
- Loans due to GSK: £3.8 million (Medicxi Ventures I LP) and £10.6 million (Index Ventures Life VI).
- Outstanding liability to Qura Therapeutics LLC: £16.1 million.
Material Changes and Unusual Items
The primary material change disclosed in this filing is the restatement of equity balances for 2018 and 2019 due to the correction of the non-controlling interest elimination from the 2018 Consumer Healthcare Joint Venture acquisition. The filing explicitly states there was no impact on profit for the year, other comprehensive income, net assets, or total equity for 2018 or 2019, nor on any items in earlier years. Additionally, GSK acquired Daiichi Sankyo's shares in Japan Vaccine Co. Ltd (JVC) during 2019, causing JVC to cease being a related party.
Guidance, Outlook, Risks, and Contingencies
The filing includes a cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks and uncertainties. Appendix A details the following principal risks and uncertainties:
- Regulatory and Legal: Risks related to compliance with global laws, product liability litigation, patent disputes, and government investigations. The filing notes GSK is a defendant in various product liability lawsuits, including class actions.
- Operational and Supply Chain: Risks regarding patient safety, product quality, and supply continuity. Specific concerns include Brexit implications for medicine supply, potential drug shortages, and the impact of global emergencies such as the coronavirus outbreak.
- Financial and Tax: Risks involving tax reform, transfer pricing disputes, and treasury activities. The filing highlights the complexity of cross-border supply routes and conflicting tax authority claims.
- Commercial and Cyber: Risks associated with anti-bribery and corruption (ABAC), commercial practices, data privacy (GDPR), and information security. The filing notes that while GSK has not experienced a material cybersecurity incident in the past year, the threat from nation-states and criminal collectives remains high.
- Research and Development: Risks regarding data integrity, ethical research practices, and the loss of patent protection leading to generic competition.
Investor Verification Checklist
- Verify the full 2019 revenue, profit, and cash flow figures in the Annual Report 2019, as they are not detailed in this Form 6-K.
- Confirm the impact of the £579 million equity adjustment on the company's financial ratios and dividend capacity.
- Review Note 46 'Legal proceedings' in the Annual Report for details on unresolved disputes and potential litigation provisions.
- Assess the specific financial impact of the coronavirus outbreak and Brexit on supply chain continuity and sales forecasts in the full Annual Report.
- Examine the related party transactions with Innoviva Inc. and Qura Therapeutics LLC for ongoing financial obligations.